The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis

Published:2019-05-22 Issue:3 Volume:50 Page:269-277
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Meyer Antoine¹²³^ORCID,Rudant Jérémie¹,Drouin Jérôme¹,Coste Joël⁴,Carbonnel Franck²³,Weill Alain¹

Affiliation:

1. Caisse Nationale de l’Assurance Maladie (CNAM); Paris France

2. Service de gastroentérologie, Bicêtre; Assistance Publique-Hôpitaux de Paris; Le Kremlin Bicêtre France

3. Université Paris Sud; Le Kremlin Bicêtre France

4. Biostatistique et Epidémiologie; Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris; Paris France

Funder

French National Health Insurance

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15323/fullpdf

Reference41 articles.

1. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis;Panaccione;Gastroenterology,2014

2. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study;Park;Ann Rheum Dis,2013

3. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study;Yoo;Ann Rheum Dis,2013

4. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation;Ben-Horin;Clin Gastroenterol Hepatol,2016

5. Biosimilars: Concepts and controversies;Gámez-Belmonte;Pharmacol Res,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System;RMD Open;2024-03

3. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22

4. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort;Scientific Reports;2022-12-06

5. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System;Scientific Reports;2022-11-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3